Immix Biopharma (IMMX) Stock Price, Quote, News & History | Benzinga

SPY777.66−0.06%QQQ741.03−0.67%BTC/USD83,404.67+2.04%DIA521.89+0.77%GLD383.73+0.41%TLT78.56+0.65%

Immix Biopharma Inc (IMMX) Stock Price, Quote, News & History

IMMXNASDAQ

Trade with Public

Trade with Public

$9.25

-0.21-2.22%

Last update: Oct 13, 7:03 AM

$9.32

-0.14-1.48%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$9.25

Volume / Avg.

44.03K / 1.63M

Day Range

$9.32 - $9.32

52 Wk Range

2.31 - 15.10

Market Cap

$766.85M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

33

Short Interest

14.72%

Days to Cover

5.11

Recent Immix Biopharma, Inc. News

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.

Vandana Singh

This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.

Avi Kapoor

This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG.

Avi Kapoor

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.

Vandana Singh

This Valaris Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Wall Street analysts make changes to top stocks. Check our analyst ratings page for all updates. VAL, BF.B mentioned.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-38.50M

Investing Cash Flow (TTM)

-9.15M

Financing Cash Flow (TTM)

261.52M

Free Cash Flow (TTM)

-39.09M

Capital Expenditure (TTM)

-591.11K

Net Change in Cash (TTM)

213.87M

Analyst Trends and Forecast

1

May

2

Jun

1

Jul

2

Aug

2

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$552.33M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.35

Earnings Yield % (TTM)

-9.52%

Earnings Yield % (FWD)

-1.10%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.76

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$225.49M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-